Canada invests in radiopharmaceuticals

The Canadian government has invested more than $911,000 to support medical and pharmaceutical research at Canada's National Laboratory for Particle and Nuclear Physics--TRIUMF--through the Western Diversification Program.

The funding will support TRIUMF in upgrading infrastructure and in the acquisition of equipment which creates positron emission radiopharmaceuticals used during PET scanning. The upgraded equipment will ensure the facility has continued compliance with industry standards, added TRIUMF. 

TRIUMF is Canada’s national laboratory for particle and nuclear physics located on the University of British Columbia campus in Vancouver, British Columbia. It is owned and operated by a consortium of 15 Canadian universities.

Around the web

The new technology shows early potential to make a significant impact on imaging workflows and patient care. 

Richard Heller III, MD, RSNA board member and senior VP of policy at Radiology Partners, offers an overview of policies in Congress that are directly impacting imaging.
 

The two companies aim to improve patient access to high-quality MRI scans by combining their artificial intelligence capabilities.